TNXP Stock — Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp (TNXP)

Updated October 16, 2026.

TNXP is a Stock. Its deepest 1-year drawdown was 70.3%.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company developing and commercializing therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases, with marketed products including TONMYA for fibromyalgia and migraine treatments, alongside a pipeline of candidates in clinical development across vaccines, antivirals, monoclonal antibodies, and other modalities. The company does not currently distribute to shareholders. Tonix appeals to investors seeking exposure to clinical-stage and early commercial-stage pharmaceutical development with potential for significant gains if pipeline candidates advance successfully, though such investments carry substantial risk of loss.

TNXP performance

Returns are updating. TNXP's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 70.3%.

TNXP key facts

Asset type

Stock

Asset class

Equity

Inception date

02/03/2012

Distribution frequency

None

Last close

$6.04 (as of 2026-10-16)

Market cap

$103,592,185

Average volume

929645.0

Payment date

11/01/2019

Beta

1.75

Payout ratio

0.0%

EPS

$-13.09

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TNXP risks and drawbacks

The deepest 1-year drawdown on record here is 70.3%.

Who may consider TNXP — and who may not

It is a weaker fit for investors who need monthly cash flow (TNXP does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TNXP

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions